Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$1,060.86 USD
+5.29 (0.50%)
Updated Jul 24, 2024 04:00 PM ET
Pre-Market: $1,065.30 +4.44 (0.42%) 8:56 AM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1,060.86 USD
+5.29 (0.50%)
Updated Jul 24, 2024 04:00 PM ET
Pre-Market: $1,065.30 +4.44 (0.42%) 8:56 AM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
Zacks News
Amgen's Xgeva Myeloma Label Expansion sBLA Accepted by FDA
by Zacks Equity Research
Amgen Inc. (AMGN) announced that the FDA has accepted its supplemental Biologics License Application (sBLA) to expand the label of its key drug, Xgeva.
Merrimack Completes Enrollment in Phase II Study for MM-141
by Zacks Equity Research
Merrimack Pharmaceuticals announced completion of enrollment in the ongoing phase II study, evaluatingMM-141 in combination with standard of care for treatment of patients with previously untreated metastatic pancreatic cancer.
CAI International, Kroger, Broadcom, Regeneron and Vodafone Group highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
CAI International, Kroger, Broadcom, Regeneron and Vodafone Group highlighted as Zacks Bull and Bear of the Day
A Lazy, Unfocused Summer Is Here: Global Week Ahead
by John Blank
A lazy, unfocused summer is here. Yet that sentiment might be bullish stocks. No new news may be good news -- in this upward trending market -- driven by momentum, mostly.
GlaxoSmithKline's Benlysta Positive in Continuation Trial
by Zacks Equity Research
GlaxoSmithKline plc (GSK) announced positive results from a phase II continuation study evaluating the efficacy and safety of its marketed drug, Benlysta, in combination with standard of care for treatment systemic lupus erythematosus (SLE).
Pfizer & Lilly Get Fast Track Designation for Pain Candidate
by Zacks Equity Research
Pfizer Inc. (PFE) and Eli Lilly and Company (LLY) announced that the FDA has granted fast track designation to their pipeline candidate, tanezumab for the treatment of chronic pain in patients with osteoarthritis (OA) and chronic low back pain (CLBP).
Zacks.com featured highlights: Regeneron Pharmaceuticals, Raymond James Financial, Dollar General, Xcel Energy and Morgan Stanley
by Zacks Equity Research
Zacks.com featured highlights: Regeneron Pharmaceuticals, Raymond James Financial, Dollar General, Xcel Energy and Morgan Stanley
GTx's (GTXI) Enobosarm Positive in Phase II Study; Shares Up
by Zacks Equity Research
GTx, Inc.'s (GTXI) shares have climbed almost 99% after the company announced positive data from a phase II study, evaluating enobosarm for treating postmenopausal women with stress urinary incontinence.
5 Stocks with Solid Sales Growth Catching Eyeballs
by Zacks Equity Research
Sales growth is an important indicator of a company's health and ability to sustain its business. It offers investors an insight into product demand and pricing power.
Lilly Plans New Outcomes Study to Expand Jardiance Label
by Zacks Equity Research
Eli Lilly and Company (LLY) along with partner Boehringer Ingelheim are planning to conduct a new outcomes study to evaluate the type II diabetes drug Jardiance (empagliflozin) for treatment of patients with chronic kidney disease.
J&J Announces EU Regulatory Approval for Actelion Deal
by Zacks Equity Research
Johnson & Johnson (JNJ) has received a regulatory approval from the European Commission (EC), thus completing all necessary formalities to close the pending acquisition of Swiss biopharmaceutical company, Actelion Ltd.
Sanofi/Regeneron's Praluent Cuts Bad Cholesterol in Studies
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that their PCSK9 inhibitor, Praluent significantly reduced bad cholesterol in two late-stage studies.
Regeneron (REGN) Up 7.3% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AstraZeneca (AZN) Divests Migraine Drug Rights Beyond Japan
by Zacks Equity Research
AstraZeneca PLC (AZN) has inked a deal to sell the global rights of migraine treatment drug Zomig (zolmitriptan) outside Japan to Grunenthal, a German pharmaceutical company.
Acorda Presents Phase III Data on PD Candidate CVT-301
by Zacks Equity Research
Acorda Therapeutics, Inc. (ACOR) presented data from a phase III study SPAN-PD, evaluating its late stage candidate CVT-301 (levodopa inhalation powder) at the International Congress of Parkinson's Disease and Movement Disorders (MDS).
Pfizer's (PFE) Tafamidis Gets Fast Track Status in the U.S.
by Zacks Equity Research
Pfizer Inc. (PFE) has been granted with fast track status by FDA for treating patients with transthyretin cardiomyopathy (TTR-CM).
Amgen Files for Repatha in the U.S., EU for Expanded Use
by Zacks Equity Research
Biotech major, Amgen, Inc. (AMGN) announced that it submitted regulatory applications for its PCSK9 inhibitor, Repatha in both the U.S. and EU.
Regeneron Announces Positive Data on Carcinoma Candidate
by Zacks Equity Research
Regeneron Pharmaceuticals and partner Sanofi announced positive results related to its experimental candidate, REGN2810, a checkpoint inhibitor targeting PD-1 in patients with advanced cutaneous squamous cell carcinoma (CSCC).
Don't Be Rip Van Winkle: Global Week Ahead
by John Blank
Not much looks to influence the markets this week -- until Thursday, when UK elections, an ECB decision and ex-FBI Commissioner James Comey testifies. Don't sleep on these potentially major events regarding market activity.
BioMarin's (BMRN) Brineura Approved by European Commission
by Zacks Equity Research
BioMarin Pharmaceutical Inc. (BMRN) announced that the European Commission has approved Brineura (cerliponase alfa) for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2).
Universal Display, Hewlett Packard, Regeneron Pharmaceuticals, Sangamo Therapeutics and Puma Biotechnology highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Universal Display, Hewlett Packard, Regeneron Pharmaceuticals, Sangamo Therapeutics and Puma Biotechnology highlighted as Zacks Bull and Bear of the Day
Teva's Migraine Candidate TEV-48125 Positive in Phase III
by Zacks Equity Research
Teva Pharmaceutical Industries Limited (TEVA) announced positive top-line results from a phase III study (HALO), evaluating its pipeline candidate, fremanezumab (TEV-48125) for prevention of chronic migraine (CM).
Eli Lilly's (LLY) Cancer Drug Cyramza Positive in Phase III
by Zacks Equity Research
Eli Lilly and Company (LLY) announced positive results from a phase III study evaluating Cyramza for expanded use in combination with docetaxel in patients with locally advanced or unresectable or metastatic urothelial carcinoma.
3 Hot Biotech Stocks to Buy in June
by Arpita Dutt
While drug pricing will remain a headline risk, here are a few biotech stocks that have performed well YTD and look well-positioned.
Pfizer's Trumenba Vaccine Approved by European Commission
by Zacks Equity Research
Pfizer Inc. (PFE) announced that its Trumenba vaccine received approval from the European Commission (EC) for active immunization of people aged 10 years and older for the prevention of invasive disease caused by Neisseria meningitidis serogroup B (MenB).